(MENAFN- EIN Presswire)
Global Respiratory disease Testing market Forecast
Respiratory disease testing companies are Koninklijke Philips N.V., Niterra., Thermo Fisher Scientific, QIAGEN, Abbott, Danaher Corp, Siemens Healthineers, etc
ALBANY, NY, UNITED STATES, January 21, 2025 /EINPresswire / -- DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual leading respiratory disease testing companies' market shares, challenges, respiratory disease testing market drivers, barriers, trends, and key market respiratory disease testing companies in the market.
The growing demand for respiratory disease testing is largely driven by the increasing global prevalence of respiratory disorders. Furthermore, the rising risk factors linked to these disorders, along with advancements in product development and regulatory approvals, are significant contributors to the expansion of the respiratory disease testing market from 2024 to 2030.
To read more about the latest highlights related to the respiratory disease testing market, get a snapshot of the key highlights entailed in the Global Respiratory Disease Testing Market Forecast
Key Takeaways from the Respiratory Disease Testing Market Report
. As per DelveInsight estimates, North America is anticipated to dominate the global respiratory disease testing market during the forecast period.
. The respiratory disease testing market was valued at USD 6.40 billion in 2023, growing at a CAGR of 4.29% during the forecast period from 2024 to 2030 to reach USD 8.55 billion by 2030.
. In the product type segment of the respiratory disease testing market, the instrument category had a significant revenue share in the respiratory disease testing market in 2023.
. Notable respiratory disease testing companies such as Koninklijke Philips N.V., Niterra Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN, Abbott, Danaher Corporation, Siemens Healthineers, Diasorin S.p.A, BD, GE Healthcare, QuantuMDx Group Ltd., BIOMÉRIEUX, SDI Diagnostics, COSMED srl, Seegene Inc., CAREstream Medical Ltd., Bird Healthcare, visby medical, Vitalograph, Bio-Rad Laboratories, Inc., and several others, are currently operating in the respiratory disease testing market.
. In August 2023, BD received FDA clearance for its BD Respiratory Viral Panel (RVP) for the BD MAXTM System. This innovative single molecular diagnostic combination test swiftly identified and differentiated SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in roughly two hours.
. In July 2023, United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, introduced Next-Generation PET/CT Systems and Integrated Molecular Technology at SNMMI.
Respiratory Disease Testing Overview
Respiratory disease testing is a critical aspect of diagnosing and managing various conditions that affect the lungs and airways, including asthma, chronic obstructive pulmonary disease (COPD), and infections like pneumonia and COVID-19. These tests help in identifying the specific cause of respiratory symptoms, such as shortness of breath, coughing, or wheezing, and can range from non-invasive procedures like spirometry and pulse oximetry to more complex methods such as chest X-rays, CT scans, and bronchoscopy. Early and accurate diagnosis through these tests allows for timely treatment, which is essential in preventing complications, managing symptoms, and improving overall patient outcomes.
Advances in technology have significantly enhanced the accuracy and speed of respiratory disease testing. Molecular testing, such as polymerase chain reaction (PCR) tests, can detect respiratory pathogens with high sensitivity, allowing for the identification of viruses and bacteria in a matter of hours. In addition, new imaging techniques and portable diagnostic devices have made it easier to diagnose and monitor respiratory conditions in various settings, including at-home care. With the ongoing evolution of these testing methods, healthcare providers are better equipped to address the challenges of respiratory diseases, ultimately leading to more personalized and effective treatment plans.
Respiratory Disease Testing Market Insights
North America held the largest share of the respiratory disease testing market in 2023, driven by the increasing prevalence of respiratory diseases in the region. The rising incidence of respiratory disorders, coupled with strong research and development efforts and a highly viable market for product development and launches, are key factors contributing to the market's growth in North America.
As respiratory disorders become more common, the demand for diagnostic testing is expected to rise, further fueling market expansion in the United States and across North America. Moreover, significant product launches in the region are also positively influencing market growth. For example, in August 2023, BD received FDA clearance for its BD Respiratory Viral Panel (RVP) for the BD MAXTM System, a groundbreaking molecular diagnostic test that quickly identifies and differentiates SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) within approximately two hours.
In summary, the factors outlined above are expected to drive the overall growth of the respiratory disease testing market in North America throughout the forecast period.
To know more about why North America is leading the market growth in the respiratory disease testing market, get a snapshot of the Respiratory Disease Testing Market Outlook:
Respiratory Disease Testing Market Dynamics
The respiratory disease testing market has undergone significant transformation over the past few years, driven primarily by the growing incidence of respiratory infections, advancements in diagnostic technologies, and the impact of the COVID-19 pandemic. The pandemic has especially highlighted the critical need for rapid and accurate diagnostic tests, propelling market growth and innovation. Governments and healthcare organizations worldwide have increased investments in respiratory disease testing infrastructure, further driving market expansion.
Technological advancements play a crucial role in shaping the dynamics of the respiratory disease testing market. The development of molecular diagnostic technologies, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), has improved the accuracy and speed of disease detection. These advancements are not only essential for identifying common respiratory pathogens like influenza and respiratory syncytial virus but are also crucial in detecting emerging pathogens. Additionally, the integration of artificial intelligence (AI) and machine learning in diagnostic tools has enhanced the ability to interpret test results more accurately, thereby improving patient outcomes.
The market is also influenced by the increasing awareness and demand for point-of-care (POC) testing. POC tests offer the advantage of quick results, often within minutes, which is critical in managing and controlling respiratory diseases, particularly in pandemic situations. The convenience and speed of POC tests have led to their widespread adoption in various settings, including hospitals, clinics, and even home care. This trend is expected to continue, driven by the need for rapid diagnostics and the ongoing development of portable and easy-to-use testing devices.
However, the respiratory disease testing market faces challenges such as high costs associated with advanced diagnostic tests and regulatory hurdles. While innovations are rapidly evolving, the regulatory approval process can be lengthy and complex, potentially delaying the introduction of new products to the market. Moreover, disparities in access to testing, particularly in low- and middle-income countries, remain a significant concern, highlighting the need for affordable and accessible diagnostic solutions.
Get a sneak peek at the respiratory disease testing market dynamics @ Respiratory Disease Testing Market Dynamics Analysis
Respiratory Disease Testing Market Assessment
. Coverage: Global
. Study Period: 2021–2030
. Respiratory Disease Testing Market CAGR: ~4%
. Respiratory Disease Testing Market Size by 2030: ~USD 9 Billion
. Key Respiratory Disease Testing Companies: Koninklijke Philips N.V., Niterra Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN, Abbott, Danaher Corporation, Siemens Healthineers, Diasorin S.p.A, BD, GE Healthcare, QuantuMDx Group Ltd., BIOMÉRIEUX, SDI Diagnostics, COSMED srl, Seegene Inc., CAREstream Medical Ltd., Bird Healthcare, visby medical, Vitalograph, Bio-Rad Laboratories, Inc., among others
. Respiratory Disease Testing Market Segmentation
o Respiratory Disease Testing Market Segmentation By Product Type: Instruments and Reagents & Kits
o Respiratory Disease Testing Market Segmentation By Test Type: Imaging, In Vitro Diagnostics, Mechanical Test, and Blood Gas Test
o Respiratory Disease Testing Market Segmentation By Disease: Lung Cancer, Tuberculosis, Asthma and COPD, and Others
o Respiratory Disease Testing Market Segmentation By End User: Hospitals & Clinics, Diagnostics Centres, and Others
o Respiratory Disease Testing Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
. Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the respiratory disease testing market are set to emerge as the trendsetter explore @ Respiratory Disease Testing Companies and Tests
Table of Contents
1. Respiratory Disease Testing Market Report Introduction
2. Respiratory Disease Testing Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Respiratory Disease Testing Market Key Factors Analysis
6. Respiratory Disease Testing Market Porter's Five Forces Analysis
7. Respiratory Disease Testing Market Layout
8. Respiratory Disease Testing Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
Interested in knowing the respiratory disease testing market by 2030? Click to get a snapshot of the Respiratory Disease Testing Market Trends:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN21012025003118003196ID1109115142